Tag: NVAX

MTSL Issue 897

MTSL Issue 897 (dated 2/28/19) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: ACAD, ALKS, FRPX, IONS, MDGL, NKTR, NVAX, PCRX, SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 893

MTSL Issue 893 (dated 1/3/18) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #INCY #NVAX #PCRX #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 867

UPDATES: BMRN, INCY, IONS, MDGL, NKTR, NVAX, SGMO, December 21, 2017 IN THIS ISSUE: MDGL, NKTR & SGMO: The Three Amigos Will Rise Again in 2018 Since Last Issue: BTK: 0.0%; NBI: 2.6%; Model Portfolio: 2.6%; Trader’s Portfolio: 2.4% Clinical Trials Watch Relevant New Studies or Changes Posted on ClinicalTrials.gov for our MTSL Portfolio and/or[…]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 858

MTSL Issue 858 (dated 8/17/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #ANTH #BMRN #ESPR #FPRX #INCY #IONS #MDCO #MDGL #NKTR #PCRX #SGMO #XON #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by
Novavax

Novavax (NVAX) — ResVax Misses Primary Endpoint, Dropping Coverage

BioInvest News Novavax (NVAX) – This morning, NVAX reported disappointing top-line data from the ResVax Phase III PREPARE study for infant RSV prevention. Unfortunately, the trial failed on the primary endpoint of reducing medically significant RSV lower respiratory tract infection (LRTI).

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 884

MTSL Issue 884 (dated 08/23/18) of Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #FPRX #IONS #NKTR #NVAX #MDGL #SGMO #ZIOP

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 866

MTSL Issue 866 (dated 12/07/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #MDGL #MDCO #NVAX

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 857

MTSL Issue 857 (dated 7/27/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ALKS #ESPR #INCY #IONS #MDCO #NKTR #NVAX #PCRX

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 895

MTSL Issue 895 (dated 1/31/18) of the Medical Technology Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #IONS #ionis #NVAX #novavax #SGMO #sangamo #MDCO #medicinescompany

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 872

MTSL Issue 872 (dated 03/01/18) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ACAD #FPRX #IONS #MDCO #NKTR #NVAX #PCRX #SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by

MTSL Issue 859

MTSL Issue 859 (dated 8/31/17) of Medical Technology #Stock Letter from BioInvest includes #Biotech Sector Analysis & updates: #ANTH #BMRN #FPRX #INCY #IONS #DCO NKTR #NVAX SGMO

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by
Novavax

Novavax (NVAX) Delivers Some Positive Phase II Immunogenicity Data In COPD

BioInvest News – NVAX – Delivers Some Positive Phase II Immunogenicity Data In COPD…Investors Wanted an RSV Update – NVAX reported top line data from the Phase II older adult safety and immunogenicity trial (E205) demonstrated the benefit of adjuvant formulations and two-dose regimens in patients with RSV and chronic obstructive pulmonary disease (COPD).

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Please login if you are a current subscriber. Thank you.

Posted on by